National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine
A cell-based vaccine composed of autologous dendritic cells (DCs) pulsed with lysates from heat-treated allogeneic melanoma tumor cells. Upon administration, this vaccine may stimulate anti-tumoral cytotoxic T-cell and antibody responses to melanoma cells bearing shared melanoma antigens such as MelanA/MART-1, gp100, MAGE3, resulting in tumor cell lysis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:Allogeneic Melanoma Cell-Loaded Dendritic Cell Vaccine
US brand name:Uvidem
Code name:IDD-3



Previous:autologous Ad-CD154-transduced CLL B cells, autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes, autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes, autologous dendritic cell-adenovirus CCL21 vaccine, autologous dendritic cell-adenovirus p53 vaccine
Next:autologous dendritic cell-autologous tumor mRNA-human CD40L vaccine, autologous dendritic cell-tumor fusion vaccine, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, autologous Epstein-Barr virus-specific cytotoxic T lymphocytes, autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov